Updated on 30 June 2015
Human clinical trials for the two compounds need to be conducted to evaluate its efficacy in patients
Singapore: Scientists from the University of Maryland School Of Medicine (UMSOM) have discovered two new compounds that has successfully protected and treated mice infected with the Middle East Respiratory Syndrome (MERS) virus.
In collaboration with Regeneron, a biopharmaceutical company based in Tarrytown, New York, Maryland researchers have identified two antibodies, REGN3051 and REGN3048that showed ability to neutralize the virus in lab studies.
Lead researcher, Mr Matthew Frieman, assistant professor of microbiology and immunology at the University of Maryland School of Medicine (UMSOM), said, "Though early, this is very exciting and has real potential to help MERS patients."
Mr Freimen mentioned that human clinical trials for the two compounds need to be conducted to evaluate its efficacy in patients. The study appeared in the latest issue of the journal Proceedings of the National Academy of Sciences (PNAS).